Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

TSHA

+ Watchlist+ Portfolio

Taysha Gene Therapies, Inc.

Regulated industryDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$3.99
52-Week Range
$3.46 – $7.30
Market Cap
$1.23B
P/E (TTM)
—
EPS (TTM)
-0.42
Dividend Yield
0.00%
Advanced Metrics
Price/Book
3.44
PEG Ratio
—
Return on Equity
-54.18%
Return on Assets
-27.35%
Gross Margin
100.00%
Operating Margin
-2998.00%
Profit Margin
0.00%
Current Ratio
18.56
Debt/Equity
0.15
Total Debt
$54.59M
Free Cash Flow
$-90.18M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$860.95M

Market Snapshot

About

Taysha Gene Therapies is a clinical-stage gene therapy company focused on developing treatments for monogenic diseases of the central nervous system. The company utilizes adeno-associated virus-based gene therapies designed to deliver functional genes to address genetic mutations. Taysha is advancing a pipeline of investigational therapies for rare neurological disorders.